Your browser is no longer supported. Please, upgrade your browser.
MRK Merck & Co., Inc. weekly Stock Chart
MRK [NYSE]
Merck & Co., Inc.
IndexDJIA S&P500 P/E23.81 EPS (ttm)3.72 Insider Own0.07% Shs Outstand2.56B Perf Week-3.26%
Market Cap226.36B Forward P/E15.80 EPS next Y5.61 Insider Trans-7.36% Shs Float2.54B Perf Month-3.30%
Income9.67B PEG2.37 EPS next Q1.15 Inst Own77.60% Short Float0.99% Perf Quarter8.93%
Sales45.97B P/S4.92 EPS this Y33.00% Inst Trans0.05% Short Ratio3.01 Perf Half Y8.33%
Book/sh10.49 P/B8.44 EPS next Y8.16% ROA11.20% Target Price99.06 Perf Year17.39%
Cash/sh3.14 P/C28.23 EPS next 5Y10.05% ROE34.30% 52W Range72.05 - 92.64 Perf YTD-2.63%
Dividend2.44 P/FCF66.46 EPS past 5Y10.60% ROI11.70% 52W High-4.40% Beta0.57
Dividend %2.76% Quick Ratio1.00 Sales past 5Y-0.80% Gross Margin70.50% 52W Low22.91% ATR1.10
Employees69000 Current Ratio1.30 Sales Q/Q14.90% Oper. Margin25.60% RSI (14)43.24 Volatility1.18% 1.13%
OptionableYes Debt/Eq0.97 EPS Q/Q1.50% Profit Margin20.30% Rel Volume1.47 Prev Close89.65
ShortableYes LT Debt/Eq0.84 EarningsFeb 05 BMO Payout61.00% Avg Volume8.37M Price88.56
Recom1.90 SMA20-2.27% SMA500.04% SMA2005.48% Volume12,593,987 Change-1.22%
Jan-07-20Initiated RBC Capital Mkts Sector Perform $99
Oct-17-19Resumed BofA/Merrill Neutral $90
Aug-16-19Initiated SVB Leerink Outperform
Jul-03-19Initiated Mizuho Buy $97
May-28-19Initiated Goldman Neutral
May-13-19Upgrade Atlantic Equities Neutral → Overweight
Oct-16-18Reiterated Citigroup Buy $70 → $79
Oct-09-18Resumed Guggenheim Buy
Apr-23-18Upgrade Goldman Neutral → Buy
Apr-17-18Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-05-18Upgrade Barclays Equal Weight → Overweight $62 → $64
Mar-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Feb-14-18Reiterated Leerink Partners Mkt Perform $67 → $66
Feb-07-18Reiterated Morgan Stanley Equal-Weight $60 → $63
Jan-16-18Upgrade SunTrust Hold → Buy
Nov-28-17Resumed BofA/Merrill Buy $64
Nov-24-17Reiterated Deutsche Bank Hold $62 → $59
Oct-31-17Upgrade Jefferies Underperform → Hold
Oct-30-17Downgrade SunTrust Buy → Hold
Oct-30-17Downgrade Morgan Stanley Overweight → Equal-Weight
Jan-23-20 06:00PM  Gilead, Bristol-Myers Pumped More Into R&D Than Shareholder Enrichments GuruFocus.com
05:29PM  US Indexes End Mostly Flat Again on Thursday GuruFocus.com
02:37PM  Dow flat in spite of losses in Travelers, Nike stocks MarketWatch
01:24PM  Travelers, Walt Disney share losses contribute to Dow's nearly 100-point drop MarketWatch
11:01AM  BioLineRx Concludes Recruitment in Pancreatic Cancer Study Zacks
08:46AM  Pfizer (PFE) Q4 Earnings Coming Up: What's in the Cards? Zacks
07:31AM  Health Canada Approves KEYTRUDA® (pembrolizumab) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma (RCC) CNW Group
Jan-22-20 10:33AM  J&J's (JNJ) Q4 Earnings Surpass Estimates, Sales Fall Short Zacks
10:03AM  Horizon Therapeutics Gets FDA Approval for Eye Drug Tepezza Zacks
09:20AM  5 Big Drug/Biotech Stocks Set to Trump Q4 Earnings Estimates Zacks
06:30AM  BriaCell Invited to Present at Mount Sinais Frontiers in Academic Pathology Symposium at The New York Academy of Medicine GlobeNewswire
Jan-21-20 01:59PM  Dow drops 166 points on losses in Boeing, Chevron shares MarketWatch
09:07AM  Value stocks are making a comeback, and heres how to get in early MarketWatch
06:55AM  FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in HRR-Mutated Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review Business Wire
Jan-20-20 09:35AM  Is Merck & Co. (MRK) a Profitable Pick for Value Investors? Zacks
09:32AM  Seattle Genetics Up More Than 40% in the Past Year: Here's Why Zacks
Jan-18-20 09:00AM  Significant Study on Veterinary Wellbeing Reveals Importance of Continued Focus on Personal and Professional Health and Wellbeing Among Veterinarians PR Newswire
02:40AM  Drugmakers slash prices to be eligible for China's bulk-buy program Reuters
Jan-17-20 08:19AM  Will J&J (JNJ) Roll Out Pharma Q4 Earnings With a Beat? Zacks
08:11AM  Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates Zacks
06:30AM  Why Amarin Stock Is Poised for a Healthy 2020 InvestorPlace
Jan-16-20 10:32AM  US Indexes Close Higher Wednesday With China Trade Deal Signing GuruFocus.com
09:09AM  Clovis Rubraca sNDA for Prostate Cancer Gets Priority Review Zacks
08:52AM  Bristol-Myers' Opdivo-Yervoy sBLA for NSCLC Accepted by FDA Zacks
08:34AM  Merck Completes Acquisition of ArQule Business Wire
Jan-15-20 03:23PM  Dow up 75 points on gains for UnitedHealth, Visa stocks MarketWatch
12:10PM  Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report? Zacks
10:48AM  UnitedHealth, Pfizer share gains lead Dow's 150-point climb MarketWatch
09:56AM  BioLineRx's Pancreatic Cancer Drug Gets Orphan Drug Tag in EU Zacks
09:47AM  Dow's 75-point climb led by gains in UnitedHealth, Pfizer stocks MarketWatch
Jan-14-20 05:45PM  Merck (MRK) Gains As Market Dips: What You Should Know Zacks
01:03PM  Merck Sharp & Dohme Corp. -- Moody's announces completion of a periodic review of ratings of Merck & Co., Inc. Moody's
09:46AM  AstraZeneca to End Phase III Study on Fish Oil Heart Drug Zacks
Jan-13-20 09:14AM  Nektar Up 25% as Bristol-Myers Expands Bempeg Collaboration Zacks
06:55AM  FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) as First-Line Maintenance with Bevacizumab in Advanced Ovarian Cancer and Grants Priority Review Business Wire
06:30AM  BriaCell Provides Update on Remarkable Responder GlobeNewswire
Jan-10-20 03:56PM  Stock Market Gives Back Early Gains After Weakish Jobs Data; These Chinese Growth Stocks Continue To Rise Investor's Business Daily
01:02PM  Amarin Stock Bouncing Back After Revised Results and 2020 Guidance InvestorPlace
10:01AM  S&P 5,000? Why one fund manager says that milestone may be reached sooner than you would expect MarketWatch
Jan-09-20 10:31AM  Blueprint Medicines Posts Data From NSCLC Study on Pralsetinib Zacks
09:00AM  Verastem In-Licenses KRAS-Focused Drug From Chugai, Stock Up Zacks
08:43AM  Merck's Keytruda Gets FDA Nod for High-Risk Bladder Cancer Zacks
06:30AM  BriaCell Outlines New High Responding Patient Group Biomarker Based on Cancer Grade GlobeNewswire
Jan-08-20 05:53PM  Among Top 5 Pharma Companies, Pfizer Was the Worst Performer in 2019 GuruFocus.com
04:31PM  FDA Approves Mercks KEYTRUDA® (pembrolizumab) for Patients With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ With or Without Papillary Tumors Who Are Ineligible for or Have Elected Not to Undergo Cystectomy Business Wire
10:13AM  Exelixis to Expand Prostate Cancer Cohort of Cabometyx Study Zacks
08:13AM  3 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2020 Zacks
Jan-07-20 05:49PM  US Indexes End Lower Tuesday GuruFocus.com
11:58AM  Dow drops 100 points on losses for Chevron, Merck shares MarketWatch
10:58AM  Dow falls 37 points on losses for Merck, Chevron shares MarketWatch
10:02AM  Merck's Keytruda Misses One of Two Goals in Lung Cancer Study Zacks
09:42AM  Pfizer/Merck KGaA's Bavencio Positive in Bladder Cancer Study Zacks
06:29AM  Merck Weighs on Dow After Clinical Trial Miss Investing.com
04:33AM  Merck Shares Dip After Keytruda Trial For Small Cell Lung Cancer Posts Uneven Results TheStreet.com
Jan-06-20 05:45PM  Merck (MRK) Outpaces Stock Market Gains: What You Should Know Zacks
04:37PM  Merck stock slides as lung-cancer drug misses a study endpoint MarketWatch
04:05PM  Mercks KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Treatment for Extensive Stage Small Cell Lung Cancer Business Wire
11:07AM  Moore Kuehn, PLLC Encourages Investors of KEM, ARQL, THOR, and LOGM to Contact the Firm PR Newswire
10:08AM  Merck signs cancer collaboration deal valued at up to $2.55B American City Business Journals
09:58AM  What Does Merck & Co., Inc.'s (NYSE:MRK) P/E Ratio Tell You? Simply Wall St.
08:25AM  Leap Therapeutics Surges on License Agreement With BieGene Zacks
08:23AM  Amgen Stock Up in a Year on Pipeline & Biosimilar Progress Zacks
06:30AM  Merck Establishes Strategic Oncology Collaboration with Taiho and Astex Business Wire
Jan-03-20 01:38PM  After Lackluster 2019, Pfizer Stock Could Rebound in 2020 InvestorPlace
11:44AM  Novartis, Merck and Allergan join those raising U.S. drug prices for 2020 Reuters
10:01AM  Incyte's (INCY) Itacitinib Fails in Late-Stage GVHD Study Zacks
09:16AM  4 Reasons Why You Should Invest in J&J (JNJ) Stock in 2020 Zacks
06:45AM  Merck to Hold Fourth-Quarter and Full-Year 2019 Sales and Earnings Conference Call on February 5 Business Wire
Jan-02-20 05:01PM  Novo Nordisk's Shares Up in a Year on Pipeline Progress Zacks
04:48PM  BriaCell Completes Share Consolidation GlobeNewswire
02:17PM  Pros' Picks: The 13 Best Dividend Stocks for 2020 Kiplinger
06:45AM  Merck to Present at the 38th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-31-19 05:45PM  Merck (MRK) Stock Sinks As Market Gains: What You Should Know Zacks
05:14PM  The Bestand WorstCompany Stocks in the Dow This Year Barrons.com
03:22PM  Dow flat in spite of losses for Walmart, Boeing stocks MarketWatch
02:49PM  More Than You Know: Innovation GuruFocus.com
10:08AM  Three Things I Learned Picking Stocks in 2019 and One New Year Investing Resolution Barrons.com
08:55AM  AstraZeneca's Lynparza Gets FDA Nod for Pancreatic Cancer Zacks
02:59AM  Best Dividend Stocks for January 2020 Investopedia
Dec-30-19 04:25PM  Dow Jones Today: A Rough Way to End 2019 InvestorPlace
02:43PM  Merck-AstraZeneca's Lynparza Snags FDA Nod For Pancreatic Cancer Benzinga
11:06AM  AstraZeneca and Merck Get a Boost as FDA Approves New Use for Cancer Drug Barrons.com
09:33AM  5 Stocks From Top-Ranked Industries Ready to Explode in 2020 Zacks
08:57AM  The Zacks Analyst Blog Highlights: AbbVie, Abbott Labs, Allergan, Johnson & Johnson and Merck Zacks
08:41AM  Nio Stock Is Soaring, Myriad Genetics Jumps, as the Dow Holds Its Ground Barrons.com
07:45AM  Myriad Genetics's stock surges after FDA approval of diagnostic test for pancreatic cancer MarketWatch
06:55AM  LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer Business Wire
Dec-27-19 04:15PM  3 Dividend-Paying Large Cap Pharma Stocks to Consider for 2020 Zacks
Dec-26-19 06:26PM  The 3 Most Popular Value Investor Podcasts of 2019 Zacks
Dec-24-19 05:45PM  Merck (MRK) Dips More Than Broader Markets: What You Should Know Zacks
12:15PM  Biotech Leading in Q4: Best ETFs & Stocks Zacks
11:36AM  Hedge Fund Consensus Stocks vs. Merck & Co., Inc. (MRK) In 2019 Insider Monkey
07:12AM  ImmunoGen Lead Drug Gets Nod for Accelerated Approval Pathway (Revised) Zacks
06:30AM  BriaCell Therapeutics Corp. Announces Share Consolidation GlobeNewswire
Dec-23-19 04:12PM  Pharma M&A Deals Likely To Be Smaller in 2020 GuruFocus.com
02:57PM  A Perspective On Biopharma's Record M&A Run In 2019 Benzinga
10:31AM  The Zacks Analyst Blog Highlights: Prologis, Best Buy and Merck Zacks
09:32AM  AstraZeneca Gets FDA Nod for New Breast Cancer Drug Enhertu Zacks
09:20AM  Bristol-Myers' Revlimid Combo Gets EU Nod for New Indication Zacks
Dec-20-19 04:53PM  US Indexes Close Higher Friday and for the Dec. 20 Week GuruFocus.com
Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases; neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. It also offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, thyroid, cervical, and brain cancers; and prevent diseases caused by human papillomavirus, as well as offers vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. In addition, the company provides antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, bovine, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fish. Further, it offers companion animal products, such as ointments; diabetes mellitus treatment and anthelmintic products; products to treat fleas and ticks in dogs and cats; horse fertility management products; dog, cat, and horse vaccines; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Intec Pharma Ltd.; Nerviano Medical Sciences; Healthy Interactions, Inc.; Oncologie, Inc.; Themis Bioscience; I-MAB Biopharma Co., Ltd.; 4D pharma plc; Promega Corporation; Seattle Genetics, Inc.; Astellas Pharma, Inc.; Seven and Eight BioPharmaceuticals Inc.; and InxMed (Shanghai) Co., Ltd. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, distributors, veterinarians, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gerberding Julie L.EVP Strat Comm, GI Pub PolicyJan 13Option Exercise0.0082,5480139,111Jan 15 05:15 PM
Gerberding Julie L.EVP Strat Comm, GI Pub PolicyJan 13Sale89.34102,0739,118,86537,038Jan 15 05:15 PM
Nally MichaelEVP, Chief Marketing OfficerOct 30Option Exercise0.002,28706,196Nov 01 05:07 PM
MIZELL STEVENEVP, Chief HR OfficerOct 30Option Exercise0.004,57404,574Nov 01 05:07 PM
Clyburn FrankEVP, Chief Commercial OfficerOct 30Option Exercise0.002,287073,032Nov 01 05:06 PM
Scholefield James HEVP,Chief Info&Digital OfficerOct 30Option Exercise0.0011,436011,436Nov 01 05:04 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 09Option Exercise0.006,427077,951Aug 12 05:13 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 09Sale85.096,427546,85071,524Aug 12 05:13 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 08Option Exercise0.0031,6990103,223Aug 12 05:13 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthAug 08Sale85.0131,6992,694,78971,524Aug 12 05:13 PM
Davis Robert MEVP, Global Svcs & CFOJun 25Option Exercise0.00216,7180354,378Jun 27 05:05 PM
Davis Robert MEVP, Global Svcs & CFOJun 25Sale85.43216,71818,514,032137,660Jun 27 05:05 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 10Option Exercise0.003,292022,412May 13 05:06 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 10Option Exercise0.004,389071,993May 13 05:05 PM
Fleming MichaelSVP Chief Ethics & Com OfficerMay 10Option Exercise0.001,50903,317May 13 05:05 PM
Nally MichaelEVP, Chief Marketing OfficerMay 10Option Exercise0.001,81104,376May 13 05:06 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 07Option Exercise39.2925,000982,25092,604May 09 06:11 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 07Sale77.7325,0001,943,18367,604May 09 06:11 PM
Zachary JenniferEVP, General CounselMay 04Option Exercise0.005,77205,772May 07 07:42 PM
Nally MichaelEVP, Chief Marketing OfficerMay 04Option Exercise0.001,29802,935May 07 07:40 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 04Option Exercise0.001,904068,542May 07 07:37 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 04Option Exercise0.001,212019,717May 07 08:32 PM
Fleming MichaelSVP Chief Ethics & Com OfficerMay 04Option Exercise0.0069202,046May 07 08:32 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthMay 03Option Exercise39.2935,0001,375,150106,064May 07 08:33 PM
DeLuca Richard R.EVP&Pres, Merck Animal HeallthMay 03Sale80.0035,0002,800,00071,064May 07 08:33 PM
Merck & Co., Inc.10% OwnerApr 08Buy16.004,121,68365,946,92812,955,016Apr 09 06:27 PM
Davis Robert MEVP, Global Svcs & CFOMar 25Option Exercise58.22192,57211,211,542330,232Mar 27 05:45 PM
Davis Robert MEVP, Global Svcs & CFOMar 25Sale82.38192,57215,863,119137,660Mar 27 05:45 PM
FRAZIER KENNETH CChairman, President & CEOMar 20Option Exercise39.29192,7367,572,597990,451Mar 20 06:49 PM
FRAZIER KENNETH CChairman, President & CEOMar 20Sale82.05192,73615,813,372797,715Mar 20 06:49 PM
FRAZIER KENNETH CChairman, President & CEOMar 13Option Exercise39.2918,725735,705816,440Mar 14 06:38 PM
FRAZIER KENNETH CChairman, President & CEOMar 13Sale82.0018,7251,535,454797,715Mar 14 06:38 PM
FRAZIER KENNETH CChairman, President & CEOMar 05Option Exercise39.296,961273,498804,676Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOMar 05Sale82.006,961570,809797,715Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOMar 04Option Exercise39.2913,144516,428810,859Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOMar 04Sale82.0113,1441,077,875797,715Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOFeb 22Option Exercise39.2953,9612,120,128745,911Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 22Sale80.0253,9614,318,089691,950Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 21Option Exercise39.2941,9921,649,866733,942Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 21Sale80.0041,9923,359,452691,950Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 19Option Exercise39.2942,7001,677,683734,650Feb 19 05:35 PM
FRAZIER KENNETH CChairman, President & CEOFeb 19Sale80.0242,7003,416,944691,950Feb 19 05:35 PM
FRAZIER KENNETH CChairman, President & CEOFeb 15Option Exercise39.2992,9133,650,552784,863Feb 19 05:35 PM
FRAZIER KENNETH CChairman, President & CEOFeb 15Sale80.0392,9137,436,162691,950Feb 19 05:35 PM
Karachun Rita ASr. VP Fince-Global ControllerFeb 14Option Exercise59.1664,6623,825,55180,837Feb 14 06:02 PM
Karachun Rita ASr. VP Fince-Global ControllerFeb 14Sale78.9664,6625,105,95116,175Feb 14 06:02 PM
WEEKS WENDELL PDirectorFeb 13Option Exercise24.305,000121,5005,100Feb 14 06:02 PM
WEEKS WENDELL PDirectorFeb 13Sale78.715,000393,548100Feb 14 06:02 PM
Chattopadhyay SanatExe V-P & Pres. MMDFeb 12Option Exercise38.1873,7272,815,241125,194Feb 14 06:02 PM
Chattopadhyay SanatExe V-P & Pres. MMDFeb 12Sale78.6273,7275,796,30651,467Feb 14 06:02 PM
BRUN LESLIE ADirectorFeb 08Option Exercise24.305,000121,5005,000Feb 11 05:33 PM
BRUN LESLIE ADirectorFeb 08Sale77.223,052235,6811,948Feb 11 05:33 PM
FRAZIER KENNETH CChairman, President & CEOFeb 05Option Exercise39.29231,5669,098,228923,516Feb 06 05:30 PM
FRAZIER KENNETH CChairman, President & CEOFeb 05Sale78.08231,56618,079,654691,950Feb 06 05:30 PM